BioSpace News Archive

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces that new data from the NUZYRA® (omadacycline) non-clinical and investigator-initiated research programs will be presented at IDWeek 2022.

Invivyd announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs.

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, announced it will report financial results for the third quarter of 2022 on Tuesday, November 8, 2022.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) will hold an investor webcast on December 14 to present clinical data from the KT-474 Phase 1 HS and AD patient cohort (Part C) and its oncology pipeline.

BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report its fiscal 2022 fourth quarter and full year financial results on Thursday, November 10, 2022.

Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its third quarter ended September 30, 2022, after the market closes on Tuesday, October 25, 2022.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced today positive 6-month interim results from the ongoing ARCH study, an open label, single-center study assessing the safety, tolerability, impact on muscle damage biomarkers, and pharmacokinetics (PK) of EDG-5506 in adults with BMD.

Labcorp (NYSE: LH), a leading global life sciences company, today announced that Kirsten Kliphouse, president of Americas, Google Cloud, has joined its Board of Directors as an independent member.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that it does not plan to hold an advisory committee meeting in connection with its review of the Company’s New Drug Application (“NDA”) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.

Biomerica, Inc., a global provider of advanced medical products, reported net sales for the three months ended August 31, 2022 of $1.67 million, versus net sales of $1.26 million for the same period in the previous year, a 30% increase.